6-K 1 ea162946-6k_tiziana.htm CURRENT REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

July 2022

 

 

Commission File Number:  0001723069

 

 

Tiziana Life Sciences Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

 

9th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

  

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On July 11, 2022, Dr. Kunwar Shailubhai, the Chief Executive Officer and Chief Scientific Officer of Tiziana Life Sciences Ltd. (the “Company”), tendered his resignation as Chief Executive Officer, Chief Scientific Officer and director to the Board of Directors for personal reasons, effective August 1, 2022. Gabriele Cerrone, Executive Chairman of the Board, has been appointed as interim Chief Executive Officer. The Company issued a press release dated July 15, 2022 with respect to this event.

 

The press release is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

 

Exhibit Index

   
Exhibit No.  
   
99.1 Tiziana Life Sciences Ltd. Press Release dated July 15, 2022

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  TIZIANA LIFE SCIENCES LTD
       
       
Date: July 15, 2022 By: /s/ Keeren Shah
    Name:  Keeren Shah
    Title: Finance Director

 

3